MoonLake Immunotherapeutics (MLTX)vsModerna Inc (MRNA)
MLTX
MoonLake Immunotherapeutics
$11.56
-3.99%
HEALTHCARE · Cap: $1.06B
MRNA
Moderna Inc
$197.28
-0.80%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
MLTX leads profitability with a 0.0% profit margin vs -141.4%. MLTX earns a higher WallStSmart Score of 28/100 (F).
MLTX
Avoid28
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MLTX.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$197.28
$62.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 11.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MLTX
The strongest argument for MLTX centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MLTX
The primary concerns for MLTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MLTX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MLTX generates stronger free cash flow (-56M), providing more financial flexibility.
Bottom Line
MLTX scores higher overall (28/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MoonLake Immunotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug delivery technology. The company is actively developing its lead candidate, a groundbreaking interleukin-17 inhibitor, currently undergoing multiple phases of clinical trials, which has the potential to transform treatment paradigms and improve patient outcomes. With a robust research pipeline and strategic collaborations, MoonLake Immunotherapeutics is poised to meet significant unmet medical needs in the immunotherapy sector, presenting substantial opportunities for institutional investors seeking exposure to the evolving biotech landscape.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?